Opinion: Our podcast ‘Why Should I Trust You?’ connects MAHA and public health. Here’s what we’ve learned
Stat News • 1/26/2026
Summary
The podcast "Why Should I Trust You?" is hosted by Tom W. Johnson and Brinda Adhikari. They discuss the disengagement of public health from MAHA and how it has deepened mistrust.
Advertisement
Lindy Score Breakdown (V4.2)
68d
Age
1
Sources
from cluster
1631
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1631/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1631/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 68 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Stat News • 2 days ago
Opinion: Medical misinformation wins when patients can’t see their doctors
Stat News • 2 days ago
Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs
Stat News • 1 day ago
STAT+: White House proposes 12% cut to federal health agencies in 2027 budget request
Stat News • Today
Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine
Stat News • 1 day ago
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • 1 day ago
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • 1 day ago
Supreme Court conversion therapy decision could ripple through medicine
Stat News • 1 day ago
STAT+: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago